Clinical Trial Update: Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating standard- and high-dose irinotecan guided by UGT1A1 genotype for first-line treatment of locally advanced colon cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colon Cancer
• Colorectal Cancer

Drugs mentioned

• Irinotecan (Camptosar) (Irinotecan)

Snippet

Sponsor: Colorectal Cancer Institute of the Heilongjiang Academy of Medical Sciences | Conditions: Colonic Neoplasms | Phase 2 | Status: UNKNOWN